What's Happening?
Niagen Bioscience, Inc., a leader in NAD+ science and healthy aging research, has announced its participation in two upcoming investor conferences in May 2026. The company will be represented by its senior leadership, including CFO Ozan Pamir and CEO
Rob Fried, at the 31st Annual Sohn Investment Conference and the 4th Annual Benchmark Consumer One-On-One Conference. These events will provide Niagen Bioscience an opportunity to showcase its innovative NAD+-boosting solutions, including its flagship product, Tru Niagen®, and Niagen™ Plus. The company is known for its rigorous scientific research and collaborations with leading institutions to advance healthspan through precision science.
Why It's Important?
Niagen Bioscience's participation in these high-profile investor conferences highlights its strategic efforts to engage with potential investors and stakeholders. The company's focus on NAD+ research positions it at the forefront of the healthy aging market, a rapidly growing sector driven by an aging population and increased interest in longevity solutions. By presenting at these conferences, Niagen aims to attract investment and partnerships that could accelerate its research and product development. The company's emphasis on scientific rigor and innovation underscores its commitment to setting industry standards in NAD+ research and healthy aging solutions.
